Weight regain begins 8 weeks after stopping anti-obesity drugs, says study
The paper 'Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications' published in BMC Medicine, an open access, transparent peer-reviewed general medical journal, also observed that at 52 weeks, the subjects of the trial still weighed less than they did before starting medication, but the weight loss was reduced compared to when they were actively taking the drugs.
11 clinical trials
The researchers Han Wu et al, from the Department of Endocrinology and Metabolism, Peking University People's Hospital, China, analysed data from 11 clinical trials with 1,573 people taking anti-obesity medication. These medications included: GLP-1 receptor agonists (such as semaglutide, liraglutide), orlistat, naltrexone-bupropion, and phentermine-topiramate. Randomised controlled trials of anti-obesity medications conducted in the population for at least four weeks and followed up for four or more weeks after discontinuation were included.
The review sought to examine the post-trial period when the drugs stop, estimate what happens to the weight of these patients, how much weight is regained, how soon do they begin to regain weight and the impact of lifestyle factors on weight. The researchers observed that people who lost more weight during treatment were more likely to regain weight, even if they continued lifestyle interventions (including diet and exercise). Those who started with a lower body mass index (BMI), meaning they were less overweight, showed more weight regain after stopping than those with higher BMI. Interestingly, people taking GLP-1-related drugs experienced more weight regain after stopping than those on other drugs, they reported in the paper.
Different weight regain was observed in subjects with different characteristics, the researchers said, adding that studies with a longer follow-up duration are required to further investigate the potential factors associated with weight change after discontinuation of treatment.
Hope to many
'This is an interesting study with robust meta analyses, but similar results have been shown in many other trials too,' says Dr. Nanditha, consultant diabetologist, Dr. A. Ramachandran's Diabetes Hospitals, Chennai. 'Any intervention, either when you step down or discontinue, will result in weight gain, even if it is lifestyle modifications.'
However, it is important to see the usefulness of these drugs in the context of the obesity epidemic. Obesity, originally, was looked upon as a risk factor, but is now considered a disease by itself. 'Earlier, we did not have many tools to treat it, now these drugs are providing hope to people who can lose weight without surgery. What is clear is that the regain will not take you back to the baseline weight, so while expensive, these drugs should be considered an investment, because the benefits go beyond weight loss,' she said.
It may be remembered that another study, published recently in the journal Obesity, showed that semaglutide and tirzepatide — injectable GLP-1 drugs for obesity — produce lower weight loss in a real-world setting, as compared to during the clinical trial, because patients discontinue treatment or use lower maintenance dosages.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
9 hours ago
- Time of India
US lawmakers press FDA to target knockoff weight-loss drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market-a problem that emerged over the last year. Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity MCA Data Science Degree Leadership PGDM Public Policy Operations Management others Others Product Management healthcare Digital Marketing MBA Technology Project Management CXO Finance Artificial Intelligence Healthcare Data Analytics Management Design Thinking Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details "We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications," they wrote in a letter to FDA commissioner Marty Makary. "Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo The group-spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey-asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the "urgency" of the situation. Live Events A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a "complete and thorough" response to the issues raised in the lawmakers' letter. "Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously," the spokesperson said. "And we are deeply committed to strengthening the oversight of imported products at US ports of entry." In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalise on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage but are no longer permitted to do so after Novo Nordisk and Eli Lilly boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalisations potentially linked to the copycat drugs, but that adverse events are likely being underreported. "We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs," said a spokesperson for Hims & Hers Health, one of the telehealth firms that sells compounded GLP-1s. "We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first." Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments.
Mint
12 hours ago
- Mint
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) More stories like this are available on
The Hindu
18 hours ago
- The Hindu
Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval
On July 25, The European Medicines Agency (EMA)'s advisory committee recommended Gilead Sciences' Lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents. Any recommendation by EMA's advisory committee has to be formally approved by the European Commission, which is expected later this year. The recommendation by the EMA's advisory committee comes about a month after the U.S. FDA on June 18, 2025 approved the injectable HIV-1 capsid inhibitor as a pre-exposure prophylaxis (PrEP). The World Health Organization welcomed the approval by FDA on June 19 and issued guidelines for use of Lenacapavir for HIV prevention on July 14. 'Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer,' the guidelines say. Studies have also shown that Lenacapavir can achieve significant viral suppression, even in cases where other drugs have failed. The FDA approved Lenacapavir is based on the 2024 results from the PURPOSE 1 and PURPOSE 2 trials, which demonstrated the safety and efficacy of the pre-exposure prophylaxis injectable across diverse populations and settings. The PURPOSE 1 was a Phase 3, double-blind, randomised trial to evaluate the safety and efficacy of twice-yearly, subcutaneous Lenacapavir for pre-exposure prophylaxis (PrEP) and was tested on 5,338 cisgender women and adolescent girls aged 16-25 across 25 sites in South Africa and three sites in Uganda. The injectable was compared with an active control arm that received once-daily oral pre-exposure prophylaxis drug Truvada (emtricitabine-tenofovir disoproxil fumarate; F/TDF). There were zero HIV infections among 2,134 participants in the Lenacapavir group, while the active control group had 39 infections among 2,136 participants. In the PURPOSE 2 Phase-3 trial involving 3,265 participants in the modified intention-to-treat analysis, two participants were infected with HIV in the arm that received the injectable, while nine participants who received the active control PrEP oral drug Truvada (emtricitabine-tenofovir disoproxil fumarate; F/TDF) were infected. The background HIV incidence in the screened population (4,634 participants) was 2.37 per 100 person-years. The trial was carried out in of cisgender men, transgender, and nonbinary individuals across 88 sites in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the U.S. Compared with the generic PrEP oral drug Truvada, which is extremely inexpensive and widely available, Lenacapavir costs $28,000 for two injections. Why would people ever prefer to use Lenacapavir considering the cost? 'Oral PrEP will be effective only if there is 100% adherence. The oral drug won't work even if it is missed for a day because the drug level will be only 24 hours,' says Dr. N. Kumarasamy, Chief and Director, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai. 'People who have the highest risk such as sex workers and gay men have to take the drug every day. Taking a tablet every day, even for a deceased patient, is so difficult. They tend to miss a dose, which is why adherence is never 100%,' he says. 'Even in the case of on-demand PrEP, where people who want to indulge in unprotected sex have to take the oral drug two days before, then throughout the period of risky behaviour and continue for two more days after risky behaviour ends, adherence never goes beyond 85-90%. PrEP will work only if the adherence is 100%.' According to Dr. Kumarasamy, despite the oral tablet being inexpensive and easy to take, the adherence is less than ideal, the reason why people are moving towards long-acting injectables that prevent HIV infection for months after an injection. Cabotegravir, which was developed as pre-exposure prophylaxis (PrEP), underwent trials in many countries and was approved for use. Cabotegravir, which is administered intramuscularly every two months, was found superior compared with every day oral PrEP tablet, and started getting implemented in certain parts of the world, Dr. Kumarasamy says. 'Since Cabotegravir has to be administered every two months, people tend to forget. The new drug Lanacapivir has been found to be effective for six months in the trials. The injectable was developed in 2021 as treatment in people who no longer respond to other drugs as they have developed resistance,' he says. Because Lenacapavir was found to be long-acting, it was repurposed as a pre-exposure prophylaxis administered subcutaneously. 'Lenacapavir is a robust molecule and is the best solution in the absence of vaccines. Even if there is going to be an HIV vaccine one day, I'm sure people will have to take the vaccine every year or something. Like a flu shot, you know if at all they are going to develop a vaccine, people may have to take it every year or every six months as a booster dose. It may not be like a one dose that is effective for years,' Dr. Kumarasamy says. 'In the absence of a HIV vaccine, I think the pre-exposure prophylaxis every six months can be considered like a vaccine.' Gilead is developing the same molecule to be administered once a year instead of every six months. They are already working on that. But it will not be a subcutaneous form but as an intramuscular injection, he says. Licensing agreements On October 2, 2024, Gilead Sciences signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic Lenacapavir. Of the six generic manufacturers, four are in India. Besides signing agreement to license generic manufacturers to make the injectable, Gilead Sciences also said that it would 'support low-cost access to the drug in high-incidence, resource-limited countries at no profit until generic manufacturers are able to fully support demand'. These countries are: Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Philippines, Rwanda, South Africa, Tanzania, Thailand, Uganda, Vietnam, Zambia and Zimbabwe. The company has licensed Dr. Reddy's Laboratories Limited, Emcure, Hetero and Mylan, a subsidiary of Viatris, to manufacture Lenacapavir in India. The companies will be permitted to supply to 120 countries. According to the press release, the agreements cover not only Lenacapavir for HIV prevention but also for HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV. According to Dr. Kumarasamy one company has already started developing the drug and Lenacapavir may become available next year once the Indian drug regulator approves it based on the results of a safety study carried out in India. As per his estimate, the generic form of Lenacapavir will cost about $100 per dose.
